Human CellExp™ Recombinant Ebolavirus BDBV Envelope Glycoprotein 1 (GP1)

(No reviews yet) Write a Review
SKU:
26-P1061
Availability:
Usually Shipped in 5 Working Days
Storage Temperature:
-20°C
Shipping Conditions:
Gel Pack
Shelf Life:
12 months
€154.00 - €450.00
Frequently bought together:

Description

Biomolecule/Target: GP

Synonyms: GP1, GP, Envelope glycoprotein, GP2 (subtype Bundibugyo,strain Uganda 2007)

Alternates names: GP1, GP, Envelope glycoprotein, GP2

Taglines: N/A

Taglines: USA

Country of Animal Origin: USA

NCBI Gene ID #.: 9487265

NCBI Gene Symbol: GP

Gene Source: Bundibugyo virus

Accession #: B8XCN0

Recombinant: Yes

Source: HEK 293 cells

Purity by SDS-PAGE #: > 95%

Assay: SDS-PAGE

Purity: N/A

Assay #2: N/A

Endotoxin Level: < 1.0 EU per/μg

Activity (Specifications/test method): N/A

Biological activity: N/A

Results: N/A

Binding Capacity: N/A

Unit Definition: N/A

Molecular Weight: 31.8 kDa

Concentration: N/A

Appearance: Lyophilized

Physical form description: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.

Reconstitution Instructions: Reconstitute in 1X PBS to the desired protein concentration.

Background Information: EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . GP1 is responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrier-decreasing effects of TNF alpha.

Amino acid sequence: N/A

Handling: Centrifuge the vial prior to opening.

Usage: For Research Use Only! Not to be used in humans

View AllClose